Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

From the Literature

  • Tisagenlecleucel Shows High, Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
  • Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with Chronic Lymphocytic Leukemia
  • How Oncology Pharmacists Can Enhance Patient Quality of Care
  • Metastasis-Free Survival for Prostate Cancer Longerwith Apalutamide than with Placebo
  • Nivolumab plus Ipilimumab Combination Improves Overall Survival in Untreated Renal-Cell Carcinoma
  • Alectinib Shows Superior Outcomes versus Crizotinib in NSCLC with ALK Mutation
  • Durvalumab Use After Chemoradiotherapy Prolongs Progression-Free Survival in Stage III NSCLC
  • Olaparib Improves Progression-Free Survival in Metastatic Breast Cancer with BRCA Mutation
  • Adding Antiandrogen to Radiation Therapy Extends Survival in Relapsed Prostate Cancer
  • Venetoclax plus Rituximab an Attractive Treatment Option for Relapsed or Refractory CLL
  • Aggressive Local Consolidative Therapy Shows Benefit in Patients with Oligometastatic Non–Small-Cell Lung Cancer
  • Lutetium-177-Dotatate Extends Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Two-Drug Combination Shows Promise for Recurrent Small-Cell Lung Cancer
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
  • Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
  • Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Personalizing Therapy for Patients with Multiple Myeloma
  • Targeting BCL2 with Venetoclax in Patients with Relapsed CLL
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma
  • Aprepitant Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Children
  • Bevacizumab for Advanced Lung Cancer Does Not Increase Risk for Hospitalization or Unexpected Toxicity
  • Daratumumab, an Anti-CD38 Monoclonal Antibody, Effective Treatment Option for Patients with Relapsed and/or Refractory Multiple Myeloma
The current treatment landscape for patients with high-risk localized prostate cancer is predominantly confined to a combination of androgen-deprivation therapy (ADT) plus radiotherapy, which has been shown to improve survival over radiotherapy alone.
Page 1 of 3
Results 1 - 10 of 29